Unknown

Dataset Information

0

The impact of the RBM4-initiated splicing cascade on modulating the carcinogenic signature of colorectal cancer cells.


ABSTRACT: A growing body of studies has demonstrated that dysregulated splicing profiles constitute pivotal mechanisms for carcinogenesis. In this study, we identified discriminative splicing profiles of colorectal cancer (CRC) cells compared to adjacent normal tissues using deep RNA-sequencing (RNA-seq). The RNA-seq results and cohort studies indicated a relatively high ratio of exon 4-excluded neuro-oncological ventral antigen 1 (Nova1-4) and intron 2-retained SRSF6 (SRSF6+intron 2) transcripts in CRC tissues and cell lines. Nova1 variants exhibited differential effects on eliminating SRSF6 expression in CRC cells by inducing SRSF6+intron 2 transcripts which were considered to be the putative target of alternative splicing-coupled nonsense-mediated decay mechanism. Moreover, the splicing profile of vascular endothelial growth factor (VEGF)165/VEGF165b transcripts was relevant to SRSF6 expression, which manipulates the progression of CRC calls. These results highlight the novel and hierarchical role of an alternative splicing cascade that is involved in the development of CRC.

SUBMITTER: Lin JC 

PROVIDER: S-EPMC5343574 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

The impact of the RBM4-initiated splicing cascade on modulating the carcinogenic signature of colorectal cancer cells.

Lin Jung-Chun JC   Lee Yuan-Chii YC   Liang Yu-Chih YC   Fann Yang C YC   Johnson Kory R KR   Lin Ying-Ju YJ  

Scientific reports 20170309


A growing body of studies has demonstrated that dysregulated splicing profiles constitute pivotal mechanisms for carcinogenesis. In this study, we identified discriminative splicing profiles of colorectal cancer (CRC) cells compared to adjacent normal tissues using deep RNA-sequencing (RNA-seq). The RNA-seq results and cohort studies indicated a relatively high ratio of exon 4-excluded neuro-oncological ventral antigen 1 (Nova1<sup>-4</sup>) and intron 2-retained SRSF6 (SRSF6<sup>+intron 2</sup>  ...[more]

Similar Datasets

| S-EPMC5247614 | biostudies-literature
| S-EPMC4741983 | biostudies-literature
| S-EPMC4174443 | biostudies-literature
| S-EPMC3602429 | biostudies-literature
| S-EPMC4865323 | biostudies-literature
| S-EPMC5974434 | biostudies-literature
| S-EPMC5954996 | biostudies-literature
| S-EPMC1893002 | biostudies-literature
| S-EPMC4159621 | biostudies-literature
| S-EPMC6262947 | biostudies-literature